Sabadell, BBVA and Arcelor double their price on the stock market in 12 months
A year after the pharmaceutical company Pfizer revolutionized the world stock markets with the announcement of the effectiveness of its vaccine , opening a new scenario in terms of market expectations and the evolution of the economy, three values of the Ibex 35 have managed to double their price of quotation.
Banking and the cycle were precisely the champions of this recovery process and, specifically, Banco Sabadell , BBVA and ArcelorMittal , which in the last twelve months have doubled their price after advancing between 104% and 112%, compared to 22% that adds the selective in that period.
Now, while this significant advance has led the Basque entity and the Mittal family steelmaker to erase the losses caused by the pandemic a long time ago, the Catalan financial company still moves 34% below the maximum pre-crisis that their titles they won in January of last year at 1.02 euros per share.
Very different is the case of BBVA, whose price is at levels that it had not visited since 2018 in the vicinity of 5.96 euros, like ArcelorMittal at 27.81 euros.
Bordering on that 100% of profits , Fluidra also appears , with 99%, which last September renewed all-time highs.
On the other hand, seven companies in the benchmark indicator incur losses in the last 12 months. The largest are those led by the pharmaceutical companies Pharma Mar and Grifols , with decreases of 47% and 30%, respectively, since November 9 of last year. It is followed by four firms linked to renewable energies. Endesa , Siemens Gamesa , Iberdrola and Solaria , which are left between 8% and 19% after the bullish rally they experienced in the final stretch of 2020 due to the sustainability boom . The only one that does not save any with these industries is ACS , which has fallen by 6% in the last year.
